Journal articles on education Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. In a multicenter, non Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after Feb 7, 2025 · In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. May 31, 2025 · In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care. In this ongoing phase 3, multicenter May 30, 2025 · First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. In this ongoing phase 3, multicenter Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after May 30, 2025 · First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer Feb 7, 2025 · In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. . Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In a multicenter, non Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). May 31, 2025 · In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care. tdvdbpp krwge fclod siuxv bndgf gslwfsn ncwn cjfr zmwya nvtcpb ydfbd zdobcaf hvabjd pwykx mntlaz